A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Nivolumab
Related studies linked through entity extraction aliases.
A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection
- Status
- COMPLETED
- Phase
- PHASE3
CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE1
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study to Evaluate the Combination of Nivolumab With ADG106 in Metastatic NSCLC
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Nivolumab for Recurrent/Metastatic Carcinosarcoma
- Status
- UNKNOWN
- Phase
- PHASE2
Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Study of NIVOLUMAB/IPILIMUMAB Maintenance in Unresectable Locally Advanced or Metastatic Urothelial Cancer
- Status
- COMPLETED
- Phase
- PHASE2
CLARA: Somatic and Germline Mechanisms That Impact Renal Cancer Immunotherapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCC
- Status
- UNKNOWN
- Phase
- PHASE2/PHASE3
Cisplatin, Nab-paclitaxel, Nivolumab With Radiotherapy After Resection of Non-Metastatic Muscle Invasive Bladder Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma
- Status
- TERMINATED
- Phase
- PHASE2
A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab
- Status
- TERMINATED
- Phase
- PHASE2
Rapid Sequencing of Approved Therapies in Patients With Metastatic or Unresectable Clear Cell Renal Cell Carcinoma
- Status
- COMPLETED
- Phase
- EARLY_PHASE1
CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer
- Status
- RECRUITING
- Phase
- PHASE1